Effect of nitric-oxide synthesis on tumour blood volume and vascular activity: a phase I study.

BACKGROUND Nitric oxide has been implicated in tumour angiogenesis and in the maintaining of vasodilator tone of tumour blood vessels. The tumour vascular effects of inhibition of nitric-oxide synthesis have not been investigated in patients with cancer. METHODS Seven women and 11 men (12 with non-small-cell lung cancer, five prostate cancer, and one cervical cancer) were recruited onto a phase I dose-escalation study and received a single dose of the nitric oxide synthase inhibitor, N-nitro-L-arginine (L-NNA). Dose escalation was done by a modified Fibonacci scale with three patients at each dose level, starting with 0.1 mg/kg. Changes in dynamic contrast-enhanced CT measures of tumour relative blood volume and transfer constant (K) were measured at 1 h and 24 h after L-NNA administration. FINDINGS In the 18 patients, toxic effects were self-limiting cardiovascular changes: three patients had Common Toxicity Criteria version 2.0 grade 1 hypertension; two had grade 1 sinus bradycardia; and one had grade 1 palpitation. L-NNA area under the curve (AUC) increased linearly with dose from 163 micromol min(-1) L(-1) at 0.1 mg/kg L-NNA to 2150 micromol min(-1) L(-1) at 0.9 mg/kg L-NNA. In eight patients that underwent dynamic CT scanning, tumour blood volume decreased 1 h after L-NNA treatment (mean 42.9% [range 12.0-62.1]; paired t test p=0.0070), which was sustained for up to 24 h (mean 33.9% [range 6.5-64.9]; p=0.035). This decrease in blood volume was associated with an increase in the number of non-perfused pixels from 7.3% (SD 5.5) at baseline to 25.1% (15.3; p=0.0089) at 1 h, and 18.2% (12.9; p=0.050) at 24 h. There was a significant correlation between L-NNA plasma AUC and the reduction in tumour blood volume at 24 h after L-NNA (r=0.83; p=0.010). INTERPRETATION We have shown in vivo in patients with cancer that nitric oxide has a role in maintaining tumour blood supply, and we provide early clinical evidence that inhibition of nitric-oxide synthesis has tumour antivascular activity.

[1]  K. Miles,et al.  Perfusion CT for the assessment of tumour vascularity: which protocol? , 2003, The British journal of radiology.

[2]  C. Crone,et al.  THE PERMEABILITY OF CAPILLARIES IN VARIOUS ORGANS AS DETERMINED BY USE OF THE 'INDICATOR DIFFUSION' METHOD. , 1963, Acta physiologica Scandinavica.

[3]  H L Fung,et al.  Reversed-phase high-performance liquid chromatography method for the analysis of nitro-arginine in rat plasma and urine. , 1996, Journal of chromatography. B, Biomedical applications.

[4]  S. Moncada,et al.  Nitric oxide: physiology, pathophysiology, and pharmacology. , 1991, Pharmacological reviews.

[5]  K. Miles,et al.  CT measurement of perfusion and permeability within lymphoma masses and its ability to assess grade, activity, and chemotherapeutic response. , 1999, Journal of computer assisted tomography.

[6]  C. Harvey,et al.  Imaging of tumour therapy responses by dynamic CT. , 1999, European journal of radiology.

[7]  Katherine W Ferrara,et al.  Quantitative Evaluation of Perfusion and Permeability of Peripheral Tumors Using Contrast-Enhanced Computed Tomography , 2004, Investigative radiology.

[8]  H. Fichte,et al.  Quantitative assessment of lung cancer perfusion using MDCT: does measurement reproducibility improve with greater tumor volume coverage? , 2006, AJR. American journal of roentgenology.

[9]  P. Kubes,et al.  Nitric oxide: an endogenous modulator of leukocyte adhesion. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[10]  R. Groszmann,et al.  Selective inhibition of tumor microvascular permeability by cavtratin blocks tumor progression in mice. , 2003, Cancer cell.

[11]  L. Ellis,et al.  Roles of Nitric Oxide Synthase Inhibition and Vascular Endothelial Growth Factor Receptor-2 Inhibition on Vascular Morphology and Function in an In vivo Model of Pancreatic Cancer , 2006, Clinical Cancer Research.

[12]  Y. Soini,et al.  Inducible nitric oxide synthase expression, apoptosis, and angiogenesis in in situ and invasive breast carcinomas. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  Ernst Klotz,et al.  Lung cancer perfusion at multi-detector row CT: reproducibility of whole tumor quantitative measurements. , 2006, Radiology.

[14]  V. Steele,et al.  Is inducible nitric oxide synthase a target for chemoprevention? , 2003, Molecular cancer therapeutics.

[15]  Richard Graham Knowles,et al.  Nitric oxide synthase activity in human gynecological cancer. , 1994, Cancer research.

[16]  V. Goh,et al.  Quantitative assessment of tissue perfusion using MDCT: comparison of colorectal cancer and skeletal muscle measurement reproducibility. , 2006, AJR. American journal of roentgenology.

[17]  Fabian Kiessling,et al.  Perfusion CT in patients with advanced bronchial carcinomas: a novel chance for characterization and treatment monitoring? , 2004, European Radiology.

[18]  K. Aldape,et al.  Expression of nitric oxide synthase in human central nervous system tumors. , 1995, Cancer research.

[19]  J. Griffiths,et al.  Effects of overexpression of dimethylarginine dimethylaminohydrolase on tumor angiogenesis assessed by susceptibility magnetic resonance imaging. , 2003, Cancer research.

[20]  P Rhodes,et al.  Roles of nitric oxide in tumor growth. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[21]  R. Jain,et al.  The role of nitric oxide in tumour progression , 2006, Nature Reviews Cancer.

[22]  M. Jinzaki,et al.  Double-Phase Helical CT of Small Renal Parenchymal Neoplasms: Correlation with Pathologic Findings and Tumor Angiogenesis , 2000, Journal of computer assisted tomography.

[23]  Yoshiya Tanaka,et al.  Nitric Oxide Synthase Activity in Human Lung Cancer , 1997, Japanese journal of cancer research : Gann.

[24]  P K Lala,et al.  Role of nitric oxide in carcinogenesis and tumour progression. , 2001, The Lancet. Oncology.

[25]  R. Jain,et al.  Role of nitric oxide in tumor microcirculation. Blood flow, vascular permeability, and leukocyte-endothelial interactions. , 1997, The American journal of pathology.

[26]  B. Carey,et al.  Quantitative Imaging in Oncology , 1996 .

[27]  R Bicknell,et al.  Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. , 1997, The Journal of clinical investigation.

[28]  H. Peterson.  Modification of tumour blood flow--a review. , 1991, International journal of radiation biology.

[29]  G. Tozer,et al.  Inhibition of nitric oxide synthase induces a selective reduction in tumor blood flow that is reversible with L-arginine. , 1997, Cancer research.

[30]  P. K. Lala,et al.  NG-nitro-L-arginine methyl ester, an inhibitor of nitric oxide synthesis, ameliorates interleukin 2-induced capillary leakage and reduces tumour growth in adenocarcinoma-bearing mice. , 1996, British Journal of Cancer.

[31]  E. Masini,et al.  Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer. , 1998, Journal of the National Cancer Institute.

[32]  J. Lorente,et al.  L‐arginine pathway in the sepsis syndrome , 1993, Critical care medicine.

[33]  T. Veikkola,et al.  Regulation of angiogenesis via vascular endothelial growth factor receptors. , 2000, Cancer research.

[34]  Kazuo Miyasaka,et al.  Lung Tumors Evaluated With FDG-PET and Dynamic CT: The Relationship Between Vascular Density and Glucose Metabolism , 2002, Journal of computer assisted tomography.

[35]  U. Engelmann,et al.  Selective expression of inducible nitric oxide synthase in human prostate carcinoma , 1998, Cancer.

[36]  R K Jain,et al.  Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. , 1990, Cancer research.

[37]  S. Mukherji,et al.  Correlation between initial and early follow-up CT perfusion parameters with endoscopic tumor response in patients with advanced squamous cell carcinomas of the oropharynx treated with organ-preservation therapy. , 2006, AJNR. American journal of neuroradiology.

[38]  C. Yi,et al.  Solitary pulmonary nodules: dynamic enhanced multi-detector row CT study and comparison with vascular endothelial growth factor and microvessel density. , 2004, Radiology.

[39]  E. M. Renkin.  Transport of potassium-42 from blood to tissue in isolated mammalian skeletal muscles. , 1959, The American journal of physiology.

[40]  R K Jain,et al.  Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[41]  G. Garcı́a-Cardeña,et al.  Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. , 1997, The Journal of clinical investigation.

[42]  Ricky T. Tong,et al.  Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer , 2004, Nature Medicine.

[43]  D. Webb,et al.  Inhibition of nitric oxide synthesis increases blood pressure in healthy humans , 1993, Journal of hypertension.

[44]  C. Harris,et al.  Nitric oxide in cancer and chemoprevention. , 2003, Free radical biology & medicine.

[45]  C. Cooper,et al.  Nitric oxide synthases: structure, function and inhibition , 2001 .

[46]  P. Huang,et al.  Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. , 1998, The Journal of clinical investigation.